Novartis expands radiotherapy manufacturing network with $85M plant in China

Language

EN CN

Home · News & Events · Novartis expands radiotherapy manufacturing network with $85M plant in China

Novartis expands radiotherapy manufacturing network with $85M plant in China

Novartis

Novartis hopes a new plant in China will help accelerate the introduction of its radiotherapy into the country. (Novartis)

When it comes to expanding radiotherapy manufacturing capacity for Lutathera and Pluvicto, Novartis is putting its money where its mouth is.

The Swiss pharma is building a new radiotherapy production facility in China with an investment of more than 600 million Chinese yuan ($84.6 million), the company said (Chinese) Friday.

The new plant is located in Haiyan in the Zhejiang province about 60 miles from Shanghai. Pending regulatory approvals, the plant is expected to be operational for local production in 2026, Novartis told Fierce Pharma. The company declined to comment on the volume of capacity at the site.

Radioligand therapy requires sophisticated technology to ensure that the medication can reach patients within hours of production, Novartis’ operations president Steffen Lang, Ph.D., said in a Chinese statement. The Haiyan facility will make sure that patients in need of these therapies receive a consistent and reliable treatment experience, he added.

The Chinese project adds to Novartis’ existing radioligand therapy manufacturing facilities in Ivrea, Italy; Zaragoza, Spain; Millburn, New Jersey; and Indianapolis, Indiana, which is pending FDA approval to supply commercial doses. Novartis is aiming to have a combined annual capacity of at least 250,000 doses from existing facilities by around 2024.

Further, the company is evaluating the possibility of establishing more production base in other key markets.

Back list Next：Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11 Previous：Nuclearelectrica and Framatome in lutetium-177 agreement